{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:36:51Z","timestamp":1783341411956,"version":"3.54.6"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The use of Bcr\u2010Abl TKI was found to be associated with hepatitis B (HBV) flares, with a more profound risk observed in females. This study was conducted to characterize the clinical features of patients with HBV flare among Bcr\u2010Abl TKI users, to estimate sex\u2010specific incidence rates of HBV flare, and to evaluate potential cumulative effect of Bcr\u2010Abl TKI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Bcr\u2010Abl TKI users with chronic HBV infection were identified from Taiwan's National Health Insurance database. The HBV flare cases were identified within the cohort. Incidence rates of HBV flare between men and women were assessed. Nested case\u2013control analysis was used to evaluate the cumulative effect of Bcr\u2010Abl TKI use on HBV flare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 415 patients with chronic HBV infection treated with Bcr\u2010Abl TKI from 2005 through 2018, 45 flare cases (28 males and 17 females) were identified. Days between Bcr\u2010Abl TKI initiation and HBV flare was 319\u2009days in women compared to 610\u2009days in men. 66.7% of the flares occurred during TKI therapy. Twelve of the 45 patients died, half of them died around 6\u2009months after hepatitis B flare. Incidence rates of HBV flare were 2.34 and 3.33 per 100 person\u2010years in males and females, respectively. Higher incidence was observed among patients with chronic myeloid leukemia. Cumulative effect of Bcr\u2010Abl TKI on HBV flare was not observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 10% of HBV carriers who used Bcr\u2010Abl TKI experienced HBV flare in Taiwan. The risk was higher in women and among patients with chronic myeloid leukemia.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5667","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T01:27:05Z","timestamp":1689730025000},"page":"1368-1377","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sex\u2010specific incidence of hepatitis B virus flares among <scp>Bcr\u2010Abl<\/scp> tyrosine kinase inhibitor users in Taiwan"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-2545","authenticated-orcid":false,"given":"Ling\u2010Yi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation  Hualien Taiwan"},{"name":"Graduate Institute of Clinical Pharmacy Tzu Chi University  Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Chao","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation  Hualien Taiwan"},{"name":"School of Medicine Tzu Chi University  Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u2010Yun","family":"Chang","sequence":"additional","affiliation":[{"name":"National Taiwan University Health Data Research Center  Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-1986","authenticated-orcid":false,"given":"K. Arnold","family":"Chan","sequence":"additional","affiliation":[{"name":"National Taiwan University Health Data Research Center  Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14639230500236818"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072\u2010008\u20109099\u20105"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010009\u20100386\u20102"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i8.1318"},{"issue":"7","key":"e_1_2_13_6_1","first-page":"3629","article-title":"Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor","volume":"34","author":"Walker EJ","year":"2014","journal-title":"Anticancer Res"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp\u2010journals\u201010018\u20101147"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.596500"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3738.3738"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5429.5429"},{"key":"e_1_2_13_11_1","unstructured":"Administration UFaD.July\u2013September 2016 report. Potential signals of serious risks\/new safety information identified by the FDA adverse event reporting system (FAERS). Assessed May 17 2022.https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/july-september-2016-report-potential-signals-serious-risksnew-safety-information-identified-fda"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4132"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01232"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1816149"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102125.1998.00817.x"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071\u2010200102060\u201000001"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.06.025"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.033"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577654"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6484"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009"},{"key":"e_1_2_13_22_1","first-page":"811","volume-title":"Pharmacoepidemiology 2005","author":"Suissa S","year":"2005"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201004\u2010495598"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.05.001"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20165"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876\u2010017\u20100735\u20101"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100175\u20100"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02302"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171313"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327113512860"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu211"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004580"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010015\u20102314\u20102"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T23:37:28Z","timestamp":1699832248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/pds.5667"],"URL":"https:\/\/doi.org\/10.1002\/pds.5667","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"2022-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}